Establishment and validation of high-throughput methods for biomarker development in SCA1/2 and 3

Establishment and validation of high-throughput methods for biomarker development in SCA1/2 and 3 - biomarker SCA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020219

Enrollment

300

Registered

2020-01-24

Start date

2020-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G00-G99

Interventions

Group 1: 3 Blood takes from SCA (1/2/3) patients around 1 year apart Group 2: 3 Blood takes from controls (no neurological disease) around 1Jahr apart

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: SCA3 disease

Exclusion criteria

Exclusion criteria: No study consent

Design outcomes

Primary

Measure	Time frame
Measuring if disease protein itself is a potential molecular marker for SCA3 disease progression. Primary outcome: ataxin-3 protein as progression marker: Yes/no	—

Secondary

Measure	Time frame
secondary aims are clinincal data (like age at onset, disease duration, clinical scores like SARA, INAS) No endpoints are defined because each measurement points stands alone.	—

Countries

Germany, Netherlands, Portugal, United Kingdom

Contacts

Public ContactJeannette Hübener-Schmid

Institut für Medizinische Genetik und Angewandte Genomik

jeannette.huebener@med.uni-tuebingen.de07071/ 29 72276

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026